U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07553481) titled 'Chemotherapy-Induced Hearing Loss and Health Inequality' on April 13.
Brief Summary: This project aims to understand how platinum-based chemotherapy affects hearing function in cancer patients from different socioeconomic backgrounds in the North West of England. Platinum-based chemotherapy drugs, such as cisplatin, are ototoxic, meaning that they cause permanent damage to the hair cells of the ear, resulting in hearing loss. Patients from more deprived backgrounds face additional risk factors to their hearing health, including limited healthcare access, greater occupational noise exposure, and poorer overall health, making them mo...